Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
24 hedge funds and large institutions have $979K invested in Statera Biopharma, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
4% less funds holding
Funds holding: 25 → 24 (-1)
20% less capital invested
Capital invested by funds: $1.22M → $979K (-$237K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$32.5K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$8.99K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$2.93K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$978 |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$587 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$197K |
| 2 |
D.E. Shaw & Co
New York
|
-$31K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.1K |
| 5 |
Neuberger Berman Group
New York
|
-$9K |
STAB Hedge Fund Activity: Q4 2014 in Review
24 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2014, worth a combined $979K — down 20% from $1.22M a quarter earlier.
Fund positioning in STAB was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $32.5K. The largest seller was Sabby Management, cutting an estimated $197K.
- 24 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2014, down from 25 in Q3 2014.
- Funds reported $979K of Statera Biopharma, Inc. Common Stock stock for Q4 2014, down 20% quarter-over-quarter.
- 5 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2014 was Virtu KCG Holdings, an estimated $32.5K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2014 was Sabby Management, an estimated $197K sold.
Based on aggregated 13F filings for Q4 2014.